Free Cash Flow (FCF): $269.60M
The free cash flow (FCF) is $269.60M. It is above its 12-month average by 13.21% ($238.14M).
TECH Free Cash Flow (FCF)
Reported quarterly free cash flow; no daily interpolation.
TECH Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
TECH Average Free Cash Flow (FCF) Chart
TECH Current vs Average Free Cash Flow (FCF) Chart
TECH Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$269.60M
FREE CASH FLOW (FCF) AVG TTM
$238.14M
FREE CASH FLOW (FCF) AVG 3Y
$236.96M
FREE CASH FLOW (FCF) AVG 5Y
$251.36M
FREE CASH FLOW (FCF) AVG 10Y
$201.23M
FREE CASH FLOW (FCF) AVG 15Y
$174.13M
FREE CASH FLOW (FCF) AVG 20Y
$154.79M
CURRENT VS TTM AVG
+13.21%
CURRENT VS 3Y AVG
+13.77%
CURRENT VS 5Y AVG
+7.26%
CURRENT VS 10Y AVG
+33.98%
CURRENT VS 15Y AVG
+54.83%
CURRENT VS 20Y AVG
+74.17%
FCF Analysis
Free Cash Flow (TTM)
$269.60M
FCF Yield
2.42%
Price/FCF
41.3
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Bio-Techne Corporation (TECH)?
- The free cash flow (FCF) for TECH stock is $269.60M.
- What is the TTM average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
- The TTM average free cash flow (FCF) for TECH stock is $238.14M.
- What is the 3Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
- The 3Y average free cash flow (FCF) for TECH stock is $236.96M.
- What is the 5Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
- The 5Y average free cash flow (FCF) for TECH stock is $251.36M.
- What is the 10Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
- The 10Y average free cash flow (FCF) for TECH stock is $201.23M.
- What is the 15Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
- The 15Y average free cash flow (FCF) for TECH stock is $174.13M.
- What is the 20Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
- The 20Y average free cash flow (FCF) for TECH stock is $154.79M.
TECH Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2026-03-31 | $269.60M |
| 2025-09-30 | $224.06M |
| 2025-03-31 | $220.75M |
| 2024-09-30 | $245.03M |
| 2024-03-31 | $251.15M |
| 2023-09-30 | $215.41M |
| 2023-03-31 | $232.73M |
| 2022-09-30 | $284.52M |
| 2022-03-31 | $301.92M |
| 2021-09-30 | $295.16M |
| 2021-03-31 | $224.58M |
| 2020-09-30 | $178.53M |
| 2020-03-31 | $170.31M |
| 2019-09-30 | $150.96M |
| 2019-03-31 | $170.97M |
| 2018-09-30 | $145.27M |
| 2018-03-31 | $135.37M |
| 2017-09-30 | $144.08M |
| 2017-03-31 | $116.62M |
| 2016-09-30 | $124.87M |
| 2016-03-31 | $123.87M |
| 2015-09-30 | $114.35M |
| 2015-03-31 | $125.07M |
| 2014-09-30 | $124.98M |
| 2014-03-31 | $111.76M |
| 2013-09-30 | $103.13M |
| 2013-03-31 | $112.75M |
| 2012-09-30 | $114.14M |
| 2012-03-31 | $117.85M |
| 2011-09-30 | $127.25M |
| 2011-03-31 | $120.82M |
| 2010-09-30 | $108.80M |
| 2010-03-31 | $102.90M |
| 2009-09-30 | $106.20M |
| 2009-03-31 | $101.62M |
| 2008-09-30 | $105.58M |
| 2008-03-31 | $98.70M |
| 2007-09-30 | $84.35M |
| 2007-03-31 | $87.20M |
| 2006-09-30 | $81.98M |
| 2006-03-31 | $71.04M |
| 2005-09-30 | $61.42M |
| 2005-03-31 | $61.88M |
| 2004-09-30 | $65.93M |
| 2004-03-31 | $58.86M |
| 2003-09-30 | $39.79M |
| 2003-03-31 | $12.85M |
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman